- Home
- TLRY vs BCSF Comparison
TLRY vs BCSF Comparison
Compare TLRY & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLRY | BCSF |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.6M | 818.0M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TLRY | BCSF |
|---|---|---|
| Price | $7.47 | $13.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $103.33 | $15.00 |
| AVG Volume (30 Days) | ★ 3.4M | 509.7K |
| Earning Date | 01-08-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 13.27% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.44 |
| Revenue | ★ $837,323,000.00 | $278,347,000.00 |
| Revenue This Year | $7.39 | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | ★ N/A | $9.43 |
| Revenue Growth | ★ 0.98 | N/A |
| 52 Week Low | $3.51 | $12.49 |
| 52 Week High | $23.20 | $19.21 |
Technical Indicators
Market Signals| Indicator | TLRY | BCSF |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 50.92 |
| Support Level | $7.41 | $13.23 |
| Resistance Level | $8.31 | $13.83 |
| Average True Range (ATR) | 0.42 | 0.38 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 32.03 | 78.36 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.